Sanes Pharmaceuticals

Sanes Pharmaceuticals is a pre-clinical stage biotechnology company focused on developing transformative therapies for neurodegenerative diseases. The company's primary focus is on targeting the underlying protein misfolding and aggregation processes associated with conditions such as Alzheimer's and Parkinson's disease. By utilizing a proprietary platform to identify and optimize small molecules and peptides, Sanes aims to disrupt the progression of these debilitating disorders. Their research also extends into addressing the long-term effects of traumatic brain injury and chronic traumatic encephalopathy. Headquartered in the United States, the company is led by a team of experienced scientists and industry veterans dedicated to neuroprotection.